Introduction: Hypertension is directly responsible for 51% of all stroke deaths and 45% of all coronary heart diseases worldwide. Amlodipine besylate is a calcium channel blocker used as an anti-hypertensive agent. Valsartan is an angiotensin II receptor blocker used in the treatment of hypertension. Rationale: Fixed-dose combination products are becoming popular because of simplified dosage regimens, enhanced patient adherence and reduced costs. Therefore there is a need for analytical methods for consistent quality establishment throughout the shelf life of the product. Objective: To develop and validate UV derivative spectrophotometric and RP-HPLC methods for the simultaneous determination of Amlodipine besylate and Valsartan in tablet dosage form. To compare the developed methods by student's t-test for their suitability and sensitivity in routine quality control. Methods: For the simultaneous estimation of Amlodipine besylate and Valsartan, first, second and third order derivatization was carried out in Agilent Cary 60 UV/Vis double beam spectrophotometer. HPLC method was carried out by using Agilent 1220 Infinity LC equipped with Eclipse XDB plus C18 Column (4.6 × 150 mm, 5 μm) with a mobile phase consisting of a mixture Methanol and Acetonitrile in the ratio of 70:30 % v/v at a flow rate of 1 ml/min. Results: The developed methods were validated as per ICH guidelines in terms of accuracy, precision, LOD and LOQ. The proposed methods were found to be suitable for simultaneous determination of Amlodipine Besylate and Valsartan in bulk and in pharmaceutical dosage forms. The results of the developed methods were then compared by student's t test. Conclusion: The developed methods were found to be simple, accurate, precise and rapid for simultaneous estimation of the selected drugs. The null hypothesis from student's t-test was found to be acceptable indicating no significant difference between the results of the proposed methods. Hence depending on the availability of instruments and reagents any of the proposed methods can effectively be applied for the routine analysis of Amlodipine besylate and Valsartan in bulk and in combined pharmaceutical dosage forms..
Valsartan is an angiotensin 11 receptor blocker used in the treatment of hypertension. Chemically it is(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R) -4-hydroxy-6-oxooxan-2-yl]}-3,7-dimethyl-1,2,3,7,8,8ahexahydronaphthalen-1-yl 2,2-dimethylbutanoate. 2 It is soluble in methanol and ethanol and slightly soluble in 
EXPERIMENTAL MATERIALS AND METHODS

Instrument and Materials
An Agilent Cary 60 UV-Visible double beam Spectrophotometer with 1 cm matched quartz cells was used for all spectral measurements. HPLC separation was carried out by Agilent prominence 1220 infinity LC equipped with Eclipse XDB plus C18 column. Pharmaceutical grade working standards of Amlodipine Besylate and Valsartan were obtained from Yarrow Chem Products. Fixed dosage combination tablet containing 10 mg Amlodipine and 160 mg Valsartan was purchased from local market Hyderabad, India. All the chemicals were of HPLC grade purchased from Fisher scientific and SD -fine chemicals, Mumbai. Milli-Q water was used.
Analytical methods
UV Derivative spectroscopic method
Working standard solutions containing 30 μg/ml of Amlodipine and Valsartan were scanned in the wavelength range of 200-400 nm using Methanol as reference in Agilent Cary 60 UV/Vis spectrophotometer (version 5. 0.0.999) in derivative mode and the corresponding overlain zero order spectrum was recorded which was converted to first (Figure 3 ), second ( Figure 4 ) and third ( Figure 5 ) order derivative spectra. Each spectrum was recorded in triplicate. 3 For each replicate measurement the cell was refilled with fresh solution. One particular wavelength was selected for each drug at which the absorbance of the other was found zero. From the examination of first, second and third order overlain derivative spectra, the working wavelengths were selected as 234. 6 
RP-HPLC METHOD
HPLC separation was carried out by Agilent prominence 1220 infinity LC equipped with Eclipse XDB plus C18 column using mobile phase consisting of Methanol and Acetonitrile in the ratio of 70:30 % v/v at a flow rate of 1 ml/min. The sample injection volume was 20 μl and the UV detection was carried out at 224.1 nm for the determination of both drugs. Figure 6 shows a typical chromatogram of Amlodipine Besylate and Valsartan. The retention times for Amlodipine Besylate and Valsartan were found to be 2.533 min and 1.083 min respectively. The calibration curves for the proposed drugs showed good linearity in the concentration range of 10-60 μg/ml.
4
Procedure for the analysis of tablet formulation Twenty tablets (AMLOSARTAN) were weighed and made into a fine powder. The amount of powder equivalent to labeled claim of the drugs was taken in a volumetric flask. To it around 20 ml of solvent (Methanol) was added and the flask was placed in an ultrasonic bath for 15 min. The solution was then cooled and made up to volume with the same solvent. 5 The solution was filtered through a 0.45 μm filter and then the filtrate was used to prepare aliquots for UV-Derivative Spectroscopy and for RP-HPLC methods. The results were summarized as shown in Table 1 . Figure 7 shows a typical chromatogram of Amlodipine Besylate and Valsartan in tablet solution.
STATISTICAL METHOD OF ANALYSIS
Student's t-test
The results obtained from UV-Derivative spectroscopic and RP-HPLC methods were subjected to student's t-test to assess the suitability of the methods in regular quality control of the selected drugs. The relevant test statistic, t, is calculated from the sample data and then compared with its probable value based on t-distribution at a specified level of significance for concerning degrees of freedom for accepting or rejecting the null hypothesis.
RESULTS AND DISCUSSION
Both UVDS and HPLC methods were validated according to International Conference on Harmonization guidelines for validation of analytical procedures. 6 
Linearity
The calibration curves constructed for both the drugs showed good linearity in the concentration range of 10-50 μg/ml for Amlodipine Besylate and Valsartan in UV Derivative Spectroscopic method and 10-60 μg/ml for Amlodipine Besylate and Valsartan in HPLC method. The solutions were prepared in triplicate. The linearity was evaluated by linear regression analysis and the values were tabulated as shown in Table 2 . To check the accuracy of the proposed methods, recovery studies were carried out by applying standard addition method. A known amount of standard Amlodipine and Valsartan corresponding to 80, 100 and 120% of the label claim was added to pre-analyzed sample of the tablet. 7 The recovery studies were carried out in triplicate at each level and the results were summarized as shown in Table 3 .
Accuracy
Precision
The precision of the assay was determined by repeatability (intra-day) and intermediate precision (inter-day) studies. 8 Three sample solutions were prepared and analyzed. The results were summarized as shown in Table 4 .
Limit of detection and Limit of quantification
LOD and LOQ for the proposed methods were calculated based on the standard deviation of the analytical response and the slope of the calibration curve using the equations LOD = 3.3 σ/S and LOQ = 10 σ/S, where σ is the SD of the response and S is the slope of calibration curve as shown in Table 5 Ruggedness Ruggedness was determined by injecting the standard and sample solutions by two different analysts to check the reproducibility of the present analytical method. The results were summarized as shown in Table 6 .
Robustness
Robustness of the developed analytical method was assessed by evaluating the affect of small variations in analytical method parameters such as change in flow rate from 1.2 ml/min by ±0.2 and change in wavelength by ±2 nm. The chromatograms were recorded and the results are shown in Table 7 .
Specificity
The specificity of the proposed HPLC method was determined to check whether there is any interference due to presence of excipients, impurities or other components with the retention times of analytical peaks.
9 Figure 8 shows the chromatogram indicating specificity of the method and the results were tabulated as shown in Table 8 .
System suitability
Five replicates of working mixed standard solution were injected and the parameters like theoretical plate number (N) and tailing factor (K) were calculated to check the system suitability. 10 Figure 9 shows the chromatogram for system suitability and the results were summarized as shown in Table 9 .
Student's t-test
The results obtained in the proposed methods were subjected to student's t-test to assess the suitability of the methods in regular quality control. The t-test results obtained were tabulated as shown in Table 10 . The t-value for the 95% probability level= 2.365, since the calculated values are less than the t-table values, the null hypothesis is correct and there is no significant difference between the proposed methods. Table 9 : System suitability of the proposed method.
System suitability parameters Results
Amlodipine Valsartan
Tailing Factor 1.37 1.16
Number of theoretical plates 5110 3882 
CONCLUSION
The developed UV-derivative spectroscopic and RP-HPLC methods were found to be simple, accurate, precise and rapid for determination of Amlodipine and Valsartan in combined dosage form. The proposed UV-derivative Spectroscopic methods exploit the zero crossing technique for obtaining the first, second and third order derivative spectra indicating the simplicity of the method. The methods were found to be economical. The methods were developed and validated for various parameters as per ICH guidelines. The results obtained were within the acceptance criteria. The proposed methods were compared using student's t-test. Since the calculated t-values were found to be less than the t-table values, the null hypothesis is correct and there is no significant difference between the proposed methods. Hence, the proposed methods were found to be satisfactory and any of these two methods could be used for the routine analysis of Amlodipine Besylate and Valsartan in combined dosage form basing on the availability of instrument and reagents.
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